Please ensure Javascript is enabled for purposes of website accessibility

Why Chemours' Great Month (Up 18%) Ain't So Great

By John Bromels – Oct 8, 2016 at 7:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Chemours' stock has had a great year, up more than 190%. But that doesn't tell the whole story of this troubled company.

Chemours is a chemical company that was spun off from DuPont in 2015. Image source: Getty Images.

On the last day of September, the stock of DuPont (DD) spinoff Chemours (CC 1.48%) hit $16 a share, a high it hadn't seen in more than a year. On the first day of September, it had closed at $13.47 a share for a monthly gain of 18.8%. 

And that's just the icing on the cake. Since the beginning of August, the stock has skyrocketed 45%. While those kinds of returns are likely to make investors salivate, they don't tell the whole story.

The spark that lit the flame

Chemours' impressive run began with its better-than-expected Q2 earnings report on Aug. 9. The company reported $0.27 in adjusted EPS, crushing analysts' consensus estimate of $0.17.

Even though Chemours still posted a revenue miss of $40 million, it also reported progress in chipping away at its mountain of debt, paying down $92 million in the second quarter. It had been able to reduce expenses, raise prices on its titanium dioxide products, and grow its Opteon refrigerant business. Free cash flow was positive for a change, and the company maintained its 2016 outlook.

The company hasn't released any major news since its earnings report, so the gains since then appear to be entirely due to this lone quarterly report.

Clawing its way back

The stock's gains seem impressive, even more so when you consider its year-to-date return vs. those of its former parent DuPont and the S&P 500:

CC Chart

CC data by YCharts.

Looks incredible, to be sure. One analyst trumpeted that the stock "has been one of the top-performing stocks not only in the basic materials sector but also in the entire market since being spun out of E. I. du Pont de Nemours and Company last July."

But that's just not correct. In fact, if you look all the way back to its spinoff, a very different picture emerges:

CC Chart

CC data by YCharts.

The stock is still down 25% from its spinoff point, while DuPont and the S&P 500 are ahead (albeit by the hairs of their chinny-chin-chins). So, while investors who timed their entry incredibly well are seeing a tremendous return, everyone who was in from the beginning has lost money on the stock.

The dumping ground

Chemours' long-term underperformance isn't surprising. DuPont loaded up the new company with five times its EBITDA in net debt and numerous environmental cleanup liabilities and lawsuits -- including an estimated 2,400 asbestos-related lawsuits.

Chemours was also forced to indemnify DuPont for damages in any PFOA-related lawsuits, of which there are currently more than 3,500. The few PFOA lawsuits that have already been litigated have resulted in more than $6.7 million in damages against DuPont. DuPont is appealing, but if it's unsuccessful, Chemours may be on the hook for the entire sum. 

In exchange for buying into all this uncertainty, investors don't reap much reward. Chemours' dividend yield has been slashed to a paltry 0.77%, compared with 2.27% for DuPont. Profit margins are poor. Further PFOA litigation is looming in November.

Investor takeaway

Clearly, many investors are bullish on Chemours. They may like Chemours' forward P/E, which is much lower than its chemical peers, including DuPont's. The company is also projecting 51% year-over-year earnings growth in 2017.

But even if those rosy projections come to fruition, the company will still have massive amounts of debt to pay off, billions of dollars in possible legal liabilities, and a puny dividend. Chemours is simply too risky to jump into right now.

John Bromels has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.